新冠疫苗制造商莫德纳(Moderna, Inc.)周四公布了令人鼓舞的第三季度财报,其股价在盘前大涨逾10%。
财报数据显示,莫德纳第三季度意外实现盈利1300万美元,合每股3美分,远高于分析师此前预期的7.53亿美元亏损。公司主打新冠疫苗Spikevax在美国市场的销售额为18亿美元,同比增长3.5%,高于分析师预期的13.8亿美元。该公司表示,这主要得益于今年较早推出了COVID疫苗更新版本,确保了医疗机构的供应。
尽管公司的新型RSV疫苗销售额较低,仅1000万美元,大幅低于分析师预期的1.35亿美元。但莫德纳通过削减约50%的季度支出,部分原因是闲置产能和库存减少,从而抵消了RSV疫苗销售不佳的影响。公司重申今年的销售目标仍在30亿至35亿美元区间,并将全年销售成本占产品销售额的预测区间上限从40%-50%下调至40%-45%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.